title: Advances in adjuvant systemic therapy for non-small-cell lung cancer.
abstract: Non-small-cell lung cancer remains a leading cause of death around the world. For most cases, the only chance of cure comes from resection for localised disease, however relapse rates remain high following surgery. Data has emerged over recent years regarding the utility of adjuvant chemotherapy for improving disease-free and overall survival of patients following curative resection. This paper reviews the clinical trials that have been conducted in this area along with the studies integrating radiation therapy in the adjuvant setting. The role of prognostic gene signatures are reviewed as well as ongoing clinical trials including those incorporating biological or targeted therapies.
authors.affiliation: David Leong, Rajat Rai, Desmond Yip, Department of Medical Oncology, The Canberra Hospital, Garran, ACT 2605, Australia.
authors.forename: David
authors.initials: D
authors.lastname: Leong
authors.affiliation: David Leong, Rajat Rai, Desmond Yip, Department of Medical Oncology, The Canberra Hospital, Garran, ACT 2605, Australia.
authors.forename: Rajat
authors.initials: R
authors.lastname: Rai
authors.affiliation: David Leong, Rajat Rai, Desmond Yip, Department of Medical Oncology, The Canberra Hospital, Garran, ACT 2605, Australia.
authors.forename: Brandon
authors.initials: B
authors.lastname: Nguyen
authors.affiliation: David Leong, Rajat Rai, Desmond Yip, Department of Medical Oncology, The Canberra Hospital, Garran, ACT 2605, Australia.
authors.forename: Andrew
authors.initials: A
authors.lastname: Lee
authors.affiliation: David Leong, Rajat Rai, Desmond Yip, Department of Medical Oncology, The Canberra Hospital, Garran, ACT 2605, Australia.
authors.forename: Desmond
authors.initials: D
authors.lastname: Yip
keywords: Adjuvant; Biological therapy; Biomarker; Carcinoma; Chemotherapy; Non-small-cell lung; Radiotherapy